Differential cellular effects of sunitinib and pazopanib targeted drugs for metastatic renal cell carcinoma

an in vitro approach

Authors

  • Filipa Amaro Associate Laboratory i4HB, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Portugal. UCIBIO-REQUIMTE, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Portugal.
  • Carolina Pisoeiro Associate Laboratory i4HB, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Portugal. UCIBIO-REQUIMTE, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Portugal.
  • Maria João Valente National Food Institute, Technical University of Denmark, Kongens Lyngby, Copenhagen, Denmark
  • Vera Miranda-Gonçalves Cancer Biology & Epigenetics Group–Research Centre, Portuguese Oncology Institute of Porto, Porto, Portugal.
  • Carmen Jerónimo Cancer Biology & Epigenetics Group–Research Centre, Portuguese Oncology Institute of Porto, Porto, Portugal. Department of Pathology, Portuguese Oncology Institute of Porto, Porto, Portugal.
  • Rui Henrique Cancer Biology & Epigenetics Group–Research Centre, Portuguese Oncology Institute of Porto, Porto, Portugal. Department of Pathology, Portuguese Oncology Institute of Porto, Porto, Portugal. Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar–University of Porto, Porto, Portugal.
  • Maria de Lourdes Bastos Associate Laboratory i4HB, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Portugal. UCIBIO-REQUIMTE, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Portugal.
  • Paula Guedes de Pinho Associate Laboratory i4HB, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Portugal. UCIBIO-REQUIMTE, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Portugal.
  • Márcia Carvalho Associate Laboratory i4HB, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Portugal. UCIBIO-REQUIMTE, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Portugal. FP-I3ID, FP-BHS, University Fernando Pessoa, Porto, Portugal. Faculty of Health Sciences, Fernando Pessoa University, Porto, Portugal.
  • Joana Pinto Associate Laboratory i4HB, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Portugal. UCIBIO-REQUIMTE, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, Portugal.

DOI:

https://doi.org/10.51126/revsalus.v4iSup.401

Keywords:

renal cell carcinoma, tyrosine kinase inhibitors, antiproliferative, cytotoxicity, in vitro

Downloads

Download data is not yet available.

Downloads

Published

2022-04-06

How to Cite

Differential cellular effects of sunitinib and pazopanib targeted drugs for metastatic renal cell carcinoma: an in vitro approach. (2022). RevSALUS - International Scientific Journal of the Academic Network of Health Sciences of Lusophone, 4(Sup), 167-168. https://doi.org/10.51126/revsalus.v4iSup.401

Most read articles by the same author(s)